888PecanAve.

(956)2222222
McAllen,TX78566
info@medicapital.net

Memo:

Date:
April09,2015
To:
Dr.BrettMillan,CEO
From:
JeannetteRodriguez,ResearchAnalyst
Subject:
InvestmentChoiceforCancerTreatmentResearch
Pg.
1

Purpose:
Thepurposeofthismemorandumreportistodeterminethecompanywhoisbestsuitedfor
MediCapitalsinvestmentforresearchincancertreatments.

Summary:
Athoroughinvestigationwasmadeoneachpotentialcandidateforthepurposeofdecidingwhich
companywillreceiveMediCapitalsinvestment.Thecandidatesforthisinvestmentarethefollowing
companies:Celera,OnyxPharmaceuticals,UnitedTherapeutics,CrucellNV,andMankindCorp.A
portfolioforeachcompanyhasbeenmadethathighlightcertaincharacteristicsineachcompanysuchas
partnerships,awardsandrecognitionsfortheirwork,drugsandproductsundergoingclinicaltrials,drugs
andproductsapprovedbytheFoodandDrugAdministration(FDA),andlastbutnotleastthe52week
highandlowstockprice.Aftercloselyexaminingeachcompany,thebestchoiceforMediCapitals
investmentisOnyxPharmaceuticals.

ReasoningBehindDecision:
Althoughthecompanyportfolioforeachcandidatehighlightsthecharacteristicsmentionedabove,not
allofthemplayedamajorfactorforthisdecision.Themainfactorsthatwereconsideredweretheyears
ofexperience,currentandpastcancerrelatedresearch,aswellasthefieldexpertiseforeachcompany.
Theremainingcharacteristicscomplimentedtheirportfoliosbutplayedaminorroleinthisdecision.
ThereasonsbehindthisisduetothefactthatMediCapitalseekstoinvestincancerrelatedresearch,
therefore,thecompanyshouldhaveanexpertiserelatedtocancerresearch,haveahistoryofconducting
researchinthatfield,aswellasshowthatitisknowledgeableandhasagoodamountofexperiencein
thefieldofcancerresearch.These3maincomponentswillleadtothewisestchoiceforMediCapitals
investment.

888PecanAve.
(956)2222222
McAllen,TX78566
info@medicapital.net

Memo:

Date:
April09,2015
To:
Dr.BrettMillan,CEO
From:
JeannetteRodriguez,ResearchAnalyst
Subject:
InvestmentChoiceforCancerTreatmentResearch
Pg.
2

AnalysisofCandidates
Eachcandidateshowsapromisingfutureinthemedicalfieldthroughtheirvariousresearchprojects,yet
thebestchoiceforMediCapitalisOnyxPharmaceuticals.Outofthefivecandidates,threeofthemdid
nothaveanexpertiseorfocusincancerrelatedresearch,causingthemtoberemovedfromthelistof
candidates.TheremainingcandidateswereCeleraandOnyxPharmaceuticals.

Bothofthesecompanieshavebeeninthefieldformorethan15years,whichdemonstratesthatthey
haveextensiveexperienceandarewellestablishedintheresearchrealm.Althoughbothofthese
companieshaveanextraordinaryprofile,theytakeverydifferentapproachestoresearch.

Celeratakestheirresearchapproachingeneticmapping,whichinthelongrunwillhelpcharacterize
anddetectcertaincancersinamoreefficientmanner.Byplacingtheirfocusongeneticmapping,itwill
leadtobetterandmoreefficienttreatmentsforcancer.AlthoughCelerashowsgreatpromiseincancer
relatedresearch,theyhaveyettodeveloptherapeuticoptionsforcancerrelatedillnesses.Thisshows
thatCeleraisstillfarfromattainingthegoalofusingtheirknowledgeforbetterimprovingthelivesof
thoseaffectedwithcancer.Notonlythat,butmostoftheircancerrelatedresearchisusedtobetter
diagnosepatientswithlungandbreastcancerratherthanhelptreat,cure,ormanagetheillness.Another
notablethingthatshowstobeashortcomingonCelerawasthattheircancerrelatedresearchisonlyon
lungandbreastcancer,whichisverylimitedincomparisontootherresearchcompanies.Forthese
reasons,CeleraisnottheidealcandidateforMediCapitalsinvestment.

OnyxPharmaceuticalstakestheirresearchapproachindevelopingpharmaceuticalsthatwillhelptreat
andmanagevariouscancers.TheyhavetwodrugsthathavealreadybeenapprovedbytheFDAtotreat
thefollowingcancers:Liver,Thyroid,Kidney,andAdvancedMyeloma.CurrentlyOnyxisresearching
variouscombinationsforoneoftheirFDAapproveddrugs,andanotherdrugthatispendingonFDA
approval.Thesedrugscombinedwithdifferentformsoftherapiesareundergoingclinicaltrialsinhopes
ofimprovingandmakingtreatmentmoreefficient.MostofthepharmaceuticalsthatOnyxhas
developedaremadetotreatseveraltypesofcancer.Furthermore,Onyxhastargetedfourdifferenttypes

ofcancerin

888PecanAve.
(956)2222222
McAllen,TX78566
info@medicapital.net

Memo:

Date:
April09,2015
To:
Dr.BrettMillan,CEO
From:
JeannetteRodriguez,ResearchAnalyst
Subject:
InvestmentChoiceforCancerTreatmentResearch
Pg.
3

theirquesttodevelopeffectivepharmaceuticals.Thisnumberislargeincomparisontoother
candidates.Moreover,italsodemonstratesOnyxdeepcommitmenttofindpharmaceuticalsthatwill
betterimprovethetreatmentandmanagementofcancer,whichwillpositivelyimprovethelivesofthose
whoaresufferingwiththeseillnesses.

Conclusion:
Overall,MediCapitalsinvestmentshouldgotoOnyxPharmaceuticalssinceitbestsuitsMediCapitals
interests,andalsoprovestobeaprominentchoice.Ithas23yearsinthefield,hashadvariousdrugs
approvedbytheFDAascancertreatments,andiscurrentlydoingresearchondrugsthatshowtobevery
promising.Notonlythat,butthenumberofcancerstheyplacetheirresearchonisimpressive.Overall,
OnyxPharmaceuticalsisthebestchoiceforMediCapitaltoinvestin.

Enclosure:
Companyportfoliosforeachcandidate

OnyxPharmaceuticals
OnyxPharmaceuticals,asubsidiaryofAmgensince2012,hasbeeninbusinesssince1992.For23years,
OnyxPharmaceuticalshasstrivedindeliveringbreakthroughcancertreatmentstopatients.Onyx
emphasisisondevelopingpharmaceuticalsforcancerrelatedillnesses.

Partnerships
Onyxhaspartneredovertheyearswithmultiplecompanies,universities,andorganizationstofurther
increasethespeedandefficiencyofpharmaceuticalsforcancer.Onyxhasformedanalliancewith
severaluniversitiessuchastheUniversityofCaliforniainSanFranciscoandtheUniversityofTexas
MDCancerCenter.AlsoOnyxcollaborateswiththeMultipleMyelomaResearchFoundation(MMRF)
toacceleratemedicineapproachedformultiplemyeloma.Furthermore,OnyxandMMRFlaunched
CarfilzomibMyelomaAccessProgram(CMAP)whichisaprogramthatextendedtheaccessto
CarfilzomibtoeligiblepatientsintheUnitedStates.Onyxhasalsoformedapartnershipwiththe
AmericanLiverFoundation.

DrugsinClinicalTrials
Onyxhastwodrugsthatareundergoingclinicaltrials.Anadditionaldrugisalsoundergoingclinical
trials,howeveritisbeingdevelopedbyadifferentpharmaceuticalcompany.Abriefsummaryofthe
drugsisprovidedbelow.
1. Carfilzomibiscurrentlybeingevaluatedinclinicaltrialsasasingleagentandin
combinationswithothertherapiesacrossthespectrumofmultiplemyelomadiseasestates.
Allcombinationsthatarecurrentlybeingstudiedareatphase3ofclinicaltrials
2. Oprozomibiscurrentlybeingstudiedinanumberoftrialsformultiplemyeloma,
Waldenstromsmacroglobulinemia,andadvancedlivercancer.Fiveofthecurrent
combinationstudiesforOprozomibareatphaseoneofclinicaltrialsandonlyoneisinphase
3. Palbociclib^2isbeingdevelopedbyPfizer.Howeveritwasdiscoveredduringa
collaborativeresearchprojectbetweenOnyxandPfizer.IfPalbociclib^2isapproved,Onyx
willreceivean8%royaltyontheglobalnet.CurrentlyPalbociclib^2isonphase3of
clinicaltrials.

DrugsandProductsApprovedbytheFDA:
CurrentlyOnyxhasSorafenibapprovedbytheFDAasatreatmentforLiver,Kidney,andThyroid
CanceraswellasCarflizomibforadvancedmyeloma.

AwardsandRecognitions

CollaboratoroftheYearawardbyMultipleMyelomaResearchFoundationin2013.

Innovationsin2012Awardatthe30thAnnualNationalOrganizationforRareDiseasesGala

MultipleMyelomaResearchFoundationCorporateLeadershipAward

OutstandingProductAwardattheBayBioPantheonAwardsCeremonyin2010

OutstandingCompanyattheBayBioPantheonAwardsCeremonyin2010

AmericanLiverFoundation(ALF)PartnershipAwardin2009

StocksHighsandLows
52Weekhigh$0.0090
52weeklow$0.0001

AppleraCorpCelera
AppleCorpCelera,nownamedCelera,wasfoundedin1998,andhasbeeninthefieldfor17years.
CeleralateronbecameasubsidiaryofQuestDiagnosticsin2011.Celeraisahealthcarebusinessthat
personalizesdiseasemanagementbyusingtheirknowledgeinhumanvariability(geneticsequencing)to
providenewtestsandservices.Celeraisknownforthedevelopmentofmoleculardiagnosticproducts
thatwillhelpdetect,characterize,monitorandselecttreatmentfordisease.

Partnerships
CeleracurrentlyhasapartnershipwithAbbottLaboratoriesforthecommercializationanddevelopment
ofawiderangeofmoleculardiagnosticproducts.Abbottservestheroleofthedistributionpartnerin
thepartnership.

Celerahaspartneredandcollaboratedwithmanyinstitutionsforthesolepurposeofresearchingenetic
mappingandfurtheradvancingmedicalknowledge.SomeofthefewcollaborationsCelerahasbeenin
arewiththefollowinginstitutions:
MedcoHealthSolutionscollaborativeresearchforevaluatingtheeffectofK1F6with
patientswithcardiovasculardisease,
Ipsenresearchcollaborationfordevelopingbiomarkersandpharmacogenomictestsfor
growthfailureinpatients
Merck&Coresearchcollaborationtoidentifyandvalidategeneticmarkersusefulinthe
developmentofprognostictestsandtherapeuticsforselectedcancers.

DrugsinClinicalTrials
CurrentlyCelerahasthefollowingprojects(listedbelow)undergoingclinicaltrials,however,thestatus
oftheclinicalphasetheyareinisunclearduetonorecentpublishedupdatesontheirresearch.
1. Forinfectiousdiseases,CelerahasViroSeqHIVIntegraseAssay,ViroSeqHCVAssay,and
ViroSeqHBVAssayundergoingtrials.
2. Intheareaofgeneticsandproteomics,Celerahasresearchprojectstodiscoverefficientways
todetectgeneticmarkersforCoronaryHeartDisease,Thrombophilia,LiverFibrosis,Breast
Cancer,andLungCancer.

Drugs&ProductsApprovedbytheFDA
CurrentlyCelerahasViroSeqHIV1GenotypingSystemandRealTimeSystemforHIVViralLoad
productsapprovedbytheFDA.TheseproductshelpdetectviralandbacterialillnessessuchasHIV,
Chlamydia,Gonorrhea,HepatitisBandC.NotonlythatbutitalsohastheCysticFibrosisGenotyping
AssayapprovedbytheFDA.

AwardsandRecognitions
Therearenoknownawards,howeverCelerahashadseveraloftheirresearchfindingspublishedin
prestigiousjournalssuchasthe
AmericanJournalofHumanGenetics,HumanMolecularGenetics,
AmericanCollegeofMedicalGenetics
and
Science.

StocksHighsandLows
52Weekhigh$78.33
52weeklow$55.08

UnitedTherapeutics
UnitedTherapeuticsCorporationwasfoundedin1996.For19years,UnitedTherapeuticshasbeena
biotechnologycompanythatfocusesonthedevelopmentofuniqueproductstoaddresstheunmet
medicalneedsofpatientswithchronicandlifethreateningconditions.Theirmainexpertiseison
treatmentoptionsforpulmonaryarterialhypertension.

Partnerships
CurrentlyUnitedTherapeuticshasapartnershipwithPluristemTherapeuticsforthedevelopmentfor
PLXPADcellsfortheindicationofPulmonaryHypertension.UnitedTherapeuticshasalsobeenina
previouspartnershipswithSupernusPharmaceuticalsforthedevelopmentofUT15C,anoral
prostacyclinanalog.

DrugsandProductsinClinicalTrials:
CurrentlyUnitedTherapeuticsdoesnothaveanydrugsorproductsinclinicaltrials.

DrugsandProductsApprovedbytheFDA:
UnitedTherapeuticscurrentlyhasUnituxinapprovedasatreatmentforhighriskneuroblastoma,arare
typeofcancerthatoftenoccursinyoungchildren.OtherproductsapprovedbytheFDAisAdcirca,
Orenitram,Remodulin,andTyvasoastreatmentoptionsforpulmonaryarterialhypertension.

AwardsandRecognitions

Ranked#12inTopWorkplacesforMidSizedCompaniesin2014bytheWashingtonPost

ListedamongtheBestPlacestoWorkin2014byTriangleBusinessJournal

AwardedthePinnacleAwardin2013bytheInternationalInteriorDesignAssociation

Ranked#25inBestSmallCompaniesinAmericain2012byForbesMagazine

PlatinumAwardinthepharmaceuticalscategoryin2012byLACPVision

PlatinumAwardinthebiotechcategoryin2012byLACPVision

StocksHighsandLows
52Weekhigh:$188.35
52weeklow:$84.63

MannkindCorporation
MannkindCorporationisabiopharmaceuticalcompanyfoundedin1991.For24years,Mannkind
Corporationhasfocusedonthediscoveryanddevelopmentoftherapeuticproductsfordiseasessuchas
diabetesandcancer.Mannkindsemphasisisonproducinginnovativeandpatientfriendlytreatment
solutionsthroughtechnologythatallowspulmonarydeliveryofmedicine.MannKindsexpertiseis
mainlyondiabetesrelatedsolutions.

Partnerships
MannkindiscurrentlyinapartnershipwithSanofi,aglobalhealthcareleader,forthedevelopmentand
commercializationofAfrezzaInhalationPowder,aninsulintherapyforadultswithtype1andtype2
diabetes.

DrugsandProductsinClinicalTrials
CurrentlyMannkinddoesnothaveanydrugsorproductsundergoingclinicaltrials,howeveritcontinues
toimproveitsuserfriendlydevicessuchasitsvariousinhalersandthetechnologyitusestoefficiently
delivertreatmenttothelungs.ThedevicesincludetheDreamboat(reusableinhaler)andCricket
(disposableinhaler).ThetechnologythatMannkindcontinuestoimproveisTechnospherewhich
producesdrypowdersthatcanbeusedwithitsinhalers.

DrugsandProductsapprovedbytheFDA
MannkindCorporationcurrentlyhasAfrezza,arapidactinginhaledinsulinusedtoimprovebloodsugar
control,approvedbytheFDAasatreatmentoptionforadultswithdiabetes.

AwardsandRecognitions

NorthAmericaFrost&SullivanEntrepreneurialCompanyoftheYearAwardin2010

FacilityoftheYearforprocessinnovationin2010

FacilityoftheYearforequipmentinnovationin2010

BiotechInvestmentAwardfora1milliongrantin2007bytheMMRF

StocksHighsandLows
52Weekhigh:$11.48
52weeklow:$4.45

CrucellNV

Crucellwasfoundedin2000,howeverithasrootthatgobackto1993.Furthermore,asof2011,
CrucelljoinedtheJanssenPharmaceuticalCompaniesofJohnson&Johnson.Crucellmainlyfocuses
ondiseasepreventionbyputtingtheireffortsinthediscoveryanddevelopmentoftransformational
immunizationproductsthatwillprotectpeopleworldwidefrommajorhealththreats.

Partnerships
Crucellhaspartneredwithmajorhealthorganizationsandinstitutionsaroundtheworld,both
governmentandnongovernmentorganizations,forthesakeofdiscoveringanddeveloping
immunizationsthatcouldprotectpeoplearoundtheworldfrommajorhealththreats.Suchpartnered
organizationsinclude,butarenotlimitedtotheWorldHealthOrganization(WHO),NationalInstituteof
AllergyandInfectiousDiseases(NIAID),GlycoVaxyn,Friendship,MaxFoundation,NationalInstitute
ofHealth(NIH),BethIsraelDeaconessMedicalCenter,andtheU.S.MilitaryHIVResearchProgram.

DrugsandProductsinClinicalTrials
CurrentlyCrucellisworkingincollaborationwithvarioushealthorganizationstodevelopvaccinesthat
areefficientandaffordableworldwidetofightagainst:
1. Ebola
2. Marburg.
3. ExtraintestinalPathogenicEColi(ExPEC)
4. HIV/AIDS
5. Influenza
6. Polio
7. RespiratorySyncytialVirus(RSV)

DrugsandProductsApprovedbytheFDA
CrucellhasthefollowingvaccinesapprovedbytheFDA:
1. QuivaxemDiphtheria,Tetanus,Pertussis,HepatitisB,andHaemophilusInfluenzatypeB
(fiveinonevaccine)
2. HepavaxGeneHepatitisBVaccine
3. EpaxalHepatitisAVaccine
4. DukoralCholeravaccine
5. Inflexalseasonalinfluenzavaccine

AwardsandRecognitions

Crucellhasbeenawardedmultiplecontractsandmonetarysumsbylargeorganizationsforthe
purposeofdevelopingvaccinesandpreventativemeasurestocombathealthhazardsglobally,
especiallyinthirdworldcountries.SuchorganizationsincludebutarenotlimitedtoUNICEF,
NIH,andWHO.

StocksHighsandLows
52Weekhigh:$109.49
52weeklow:$95.10